Home
Kura Oncology

Kura Oncology Market Share Analysis for July 2026

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Health > Biotechnology and Pharmaceuticals

Domainkuraoncology.com

Year Founded2014

Employees51 - 200

Annual Revenue$25M - $50M

Kura Oncology

Kura Oncology (including company regionals)

kuraoncology.com

See more website traffic and engagement information

Kura Oncology Revenue up to July 2026 is 25M - 50M

revenue generated by Kura Oncology top domains

Kura Oncology top domains revenue over 3 years

Revenue for Kura Oncology top domains

kuraoncology.com25M - 50M

See more with Sales Intelligence

Total visits to Kura Oncology's top domains

Understand Kura Oncology market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kuraoncology.com17.9K

See more with Sales Intelligence

Avg. visit duration in Kura Oncology's top domains

Analyze Kura Oncology engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kuraoncology.com00:00:47

See more with Sales Intelligence

Avg. pageviews on Kura Oncology's top domains

See how Kura Oncology keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kuraoncology.com1.87

See more with Sales Intelligence

Kura Oncology top competitors by domain

Top similar sites in July 2026, ranked by their affinity

xencor.comCompany NameXencorEmployees201 - 500HQUnited States, California, MonroviaAnnual revenue$100M - $200MTotal visits6.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Kura Oncology

These are the website technologies, by industry, used by Kura Oncology top domains

Advertising (11)

DoubleClick

Widget (4)

Twemoji

Audio Video Media (3)

YouTube

Conversion & Analytics (2)

Google Analytics

More Technologies

11

See all

News & Signals from Kura Oncology

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKura Oncology, Inc. had revenue of $20.9M on Aug 12th '26.* Kura Oncology beat quarterly expectations: It reported an adjusted loss of $0.77 per share versus the consensus estimate of a $0.88 loss, while revenue of $20.87 million exceeded forecasts of $20.16 million.

NewsKura Oncology, Inc. has revenue of $9.1M.Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that indication.

NewsKura Oncology, Inc attended event 2026 Kidney Cancer Research Summit on Jul 14th '26.SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) - Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that updated Phase 1a results from the ongoing FIT-001 Phase 1a/1b clinical trial (NCT06026410) evaluating darlifarnib in combination with cabozantinib in advanced renal cell carcinoma (RCC) will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit (KCRS) in Boston.